Shanghai SynTheAll Pharmaceutical Co., Ltd., commonly referred to as SynTheAll, is a leading player in the pharmaceutical industry, headquartered in Shanghai, China. Established in 2004, the company has made significant strides in the development and manufacturing of high-quality active pharmaceutical ingredients (APIs) and intermediates, catering to both domestic and international markets. With a strong focus on research and development, SynTheAll offers a diverse range of products, including custom synthesis and contract manufacturing services. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies worldwide. Notably, SynTheAll has achieved several milestones in regulatory compliance, ensuring that their products meet stringent international standards. As a result, they have solidified their reputation as a reliable source of pharmaceutical solutions in a competitive landscape.
How does Shanghai SynTheAll Pharmaceutical Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Shanghai SynTheAll Pharmaceutical Co., Ltd.'s score of 51 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shanghai SynTheAll Pharmaceutical Co., Ltd., headquartered in China, currently does not report specific carbon emissions data. However, the company is committed to climate action through its association with WuXi AppTec Co., Ltd., from which it inherits certain sustainability initiatives and targets. As a current subsidiary of WuXi AppTec, Shanghai SynTheAll is aligned with the broader corporate climate commitments of its parent company. WuXi AppTec has set near-term targets for emissions reduction, indicating a proactive approach to sustainability within the pharmaceutical sector. While specific reduction targets for Shanghai SynTheAll have not been disclosed, the company is classified as "Committed" to near-term targets, reflecting its dedication to addressing climate change. The emissions data and reduction initiatives are cascaded from WuXi AppTec, which operates at a higher corporate level. This relationship underscores the importance of collaborative efforts in achieving significant climate goals within the industry. In summary, while specific emissions figures for Shanghai SynTheAll are not available, the company's commitment to climate action is evident through its alignment with WuXi AppTec's sustainability initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 6,643,770 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 144,938,320 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shanghai SynTheAll Pharmaceutical Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.